IMNN · Insider Trading
Imunon, Inc. Common Stock
Every open-market purchase and sale reported by IMNN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Michael H Tardugno | Executive Chairman of Board | A | +7,800 | +$8.42K |
| 2026-10-13 | Stacy Lindborg | President and CEO | A | +2,977 | +$3.22K |
| 2026-10-13 | Douglas Vincent Faller | Chief Medical Officer | A | +1,249 | +$1.35K |
| 2026-09-28 | Stacy Lindborg | President and CEO | A | +6,697 | +$9.44K |
| 2026-09-28 | Douglas Vincent Faller | Chief Medical Officer | A | +4,390 | +$6.19K |
| 2026-09-28 | Michael H Tardugno | Executive Chairman of Board | A | +7,169 | +$10.11K |
| 2026-09-15 | Douglas Vincent Faller | Chief Medical Officer | A | +4,211 | +$6.19K |
| 2026-09-15 | Stacy Lindborg | President and CEO | A | +5,504 | +$8.09K |
| 2026-09-15 | Michael H Tardugno | Executive Chairman of Board | A | +5,824 | +$8.56K |
| 2026-09-01 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | +$90 |
| 2026-09-01 | Douglas Vincent Faller | Chief Medical Officer | A | +3,626 | +$5.80K |
| 2026-09-01 | Michael H Tardugno | Executive Chairman of Board | A | +7,371 | +$11.79K |
| 2026-09-01 | Stacy Lindborg | President and CEO | A | +6,822 | +$10.92K |
| 2026-08-17 | Stacy Lindborg | President and CEO | A | +6,615 | +$10.91K |
| 2026-08-17 | Douglas Vincent Faller | Chief Medical Officer | A | +3,516 | +$5.80K |
| 2026-08-17 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | +$48 |
| 2026-08-17 | Michael H Tardugno | Executive Chairman of Board | A | +7,147 | +$11.79K |
| 2026-08-04 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | +$63 |
| 2026-08-04 | Michael H Tardugno | Executive Chairman of Board | A | +6,358 | +$10.11K |
| 2026-08-04 | Donald P Braun | Director | A | +6,180 | +$9.83K |
| 2026-08-04 | Douglas Vincent Faller | Chief Medical Officer | A | +3,649 | +$5.80K |
| 2026-08-04 | James E Dentzer | Director | A | +6,934 | +$11.03K |
| 2026-08-04 | Christine A Pellizzari | Director | A | +6,934 | +$11.03K |
| 2026-08-04 | Stacy Lindborg | President and CEO | A | +5,010 | +$7.97K |
| 2026-08-04 | Frederick J. Fritz | Director | A | +6,934 | +$11.03K |
| 2026-07-21 | Michael H Tardugno | Executive Chairman of Board | A | +4,603 | +$8.42K |
| 2026-07-21 | Douglas Vincent Faller | Chief Medical Officer | A | +3,082 | +$5.64K |
| 2026-07-21 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | +$104 |
| 2026-07-21 | Stacy Lindborg | President and CEO | A | +4,907 | +$8.98K |
| 2026-07-07 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | +$28 |
| 2026-07-07 | Stacy Lindborg | President and CEO | A | +2,534 | +$4.84K |
| 2026-07-07 | Douglas Vincent Faller | Chief Medical Officer | A | +1,308 | +$2.50K |
| 2026-07-07 | Michael H Tardugno | Executive Chairman of Board | A | +4,410 | +$8.42K |
| 2026-06-29 | Susan Eylward | General Counsel and Corp Sec | MIXED | +2,896 | +$4.60K |
| 2026-06-29 | Douglas Vincent Faller | Chief Medical Officer | A | +21,896 | +$37.66K |
| 2026-06-29 | Stacy Lindborg | President and CEO | A | +67,150 | +$115.50K |
| 2026-06-29 | Michael H Tardugno | Executive Chairman of Board | A | +42,519 | +$73.13K |
| 2026-06-23 | Stacy Lindborg | President and CEO | A | +1,803 | +$3.28K |
| 2026-06-23 | Michael H Tardugno | Executive Chairman of Board | A | +4,629 | +$8.42K |
| 2026-06-09 | Stacy Lindborg | President and CEO | A | +1,593 | +$3.28K |
| 2026-06-09 | Michael H Tardugno | Executive Chairman of Board | A | +4,089 | +$8.42K |
| 2026-05-27 | Donald P Braun | Director | A | +5,011 | +$11.02K |
| 2026-05-27 | Michael H Tardugno | Executive Chairman of Board | A | +3,484 | +$7.66K |
| 2026-05-27 | Frederick J. Fritz | Director | A | +10,330 | +$22.73K |
| 2026-05-27 | James E Dentzer | Director | A | +11,148 | +$24.53K |
| 2026-05-27 | Christine A Pellizzari | Director | A | +5,557 | +$12.23K |
| 2026-05-27 | Stacy Lindborg | President and CEO | A | +1,491 | +$3.28K |
| 2026-01-06 | Stacy Lindborg | President and CEO | A | +56,187 deriv. | — |
| 2026-01-06 | Frederick J. Fritz | Director | A | +5,892 deriv. | — |
| 2026-01-06 | James E Dentzer | Director | A | +4,405 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Stacy Lindborg | President and CEO | 116,952 | $143.85K |
| Michael H Tardugno | Executive Chairman of Board | 116,343 | $143.10K |
| Douglas Vincent Faller | Chief Medical Officer | 46,927 | $57.72K |
| James E Dentzer | Director | 21,897 | $26.93K |
| Frederick J. Fritz | Director | 21,031 | $25.87K |
| Donald P Braun | Director | 15,499 | $19.06K |
| Christine A Pellizzari | Director | 15,076 | $18.54K |
| Susan Eylward | General Counsel and Corp Sec | 2,896 | $3.56K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMNN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.